TGF-Β-induced IRAK-M expression in tumor-associated macrophages regulates lung tumor growth

Oncogene

Volumn 30, Issue 21, 2011, Pages 2475-2484

  Standiford, T J ^a   Kuick, R ^b   Bhan, U ^a   Chen, J ^a   Newstead, M ^a   Keshamouni, V G ^a,b  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

IRAK M; lung cancer; TGF ; Toll like receptors; tumorassociated macrophages

Indexed keywords

INDUCIBLE NITRIC OXIDE SYNTHASE; INTERLEUKIN 1 RECEPTOR ASSOCIATED KINASE 3; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL CULTURE; CANCER GROWTH; CANCER MODEL; CANCER SURVIVAL; CARCINOMA CELL; COCULTURE; COMPARATIVE STUDY; CONTROLLED STUDY; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; LEWIS CARCINOMA; LUNG ADENOCARCINOMA; LUNG CANCER; LUNG NON SMALL CELL CANCER; MALE; MOUSE; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PERITONEUM MACROPHAGE; PHENOTYPE; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR ASSOCIATED LEUKOCYTE; WILD TYPE;

ANIMALS; BLOTTING, WESTERN; CARCINOMA, LEWIS LUNG; CELL LINE; CELL LINE, TUMOR; CELLS, CULTURED; COCULTURE TECHNIQUES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; INTERFERON-GAMMA; INTERLEUKIN-1 RECEPTOR-ASSOCIATED KINASES; INTERLEUKIN-12; LUNG NEOPLASMS; MACROPHAGES; MACROPHAGES, PERITONEAL; MALE; MICE; MICE, INBRED C57BL; MICE, KNOCKOUT; MONOCYTES; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; SURVIVAL ANALYSIS; TRANSFORMING GROWTH FACTOR BETA;

ANIMALIA; MUS;

EID: 79957627922     PISSN: 09509232     EISSN: 14765594     Source Type: Journal    
DOI: 10.1038/onc.2010.619     Document Type: Article

References (44)

1. Akira S, Takeda K. (2004). Toll-like receptor signalling. Nat Rev Immunol 4: 499-511. (Pubitemid 38931765)
2. Akira S, Takeda K, Kaisho T. (2001). Toll-like receptors: critical proteins linking innate and acquired immunity. Nat Immunol 2: 675-680. (Pubitemid 32747155)
3. Balkwill F, Charles KA, Mantovani A. (2005). Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell 7: 211-217. (Pubitemid 40568680)
4. Ben-Baruch A. (2006). Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators. Semin Cancer Biol 16: 38-52. (Pubitemid 43139708)
5. Bingle L, Brown NJ, Lewis CE. (2002). The role of tumour-associated macrophages in tumour progression: implications for new anti-cancer therapies. J Pathol 196: 254-265. (Pubitemid 34189413)
6. de Vos AF, Pater JM, van den Pangaart PS, de Kruif MD, van 't Veer C, van der Poll T. (2009). In vivo lipopolysaccharide exposure of human blood leukocytes induces cross-tolerance to multiple TLR ligands. J Immunol 183: 533-542.
7. del Fresno C, Otero K, Gomez-Garcia L, Gonzalez-Leon MC, Soler-Ranger L, Fuentes-Prior P et al. (2005). Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol 174: 3032-3040. (Pubitemid 40279724)
8. Deng JC, Cheng G, Newstead MW, Zeng X, Kobayashi K, Flavell RA et al. (2006). Sepsis-induced suppression of lung innate immunity is mediated by IRAK-M. J Clin Invest 116: 2532-2542. (Pubitemid 44330152)
9. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA et al. (2005). Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 97: 1407-1427. (Pubitemid 41520077)
10. Elgert KD, Alleva DG, Mullins DW. (1998). Tumor-induced immune dysfunction: the macrophage connection. J Leukoc Biol 64: 275-290. (Pubitemid 28409233)
11. Elliott RL, Blobe GC. (2005). Role of transforming growth factor Beta in human cancer. J Clin Oncol 23: 2078-2093. (Pubitemid 46211385)
12. Gordon S. (2003). Alternative activation of macrophages. Nat Rev Immunol 3: 23-35. (Pubitemid 37328697)
13. Hasegawa Y, Takanashi S, Kanehira Y, Tsushima T, Imai T, Okumura K. (2001). Transforming growth factor-beta1 level correlates with angiogenesis, tumor progression, and prognosis in patients with nonsmall cell lung carcinoma. Cancer 91: 964-971.
14. Jacobsen SE, Keller JR, Ruscetti FW, Kondaiah P, Roberts AB, Falk LA. (1991). Bidirectional effects of transforming growth factor beta (TGF-beta) on colony-stimulating factor-induced human myelopoiesis in vitro: differential effects of distinct TGF-beta isoforms. Blood 78: 2239-2247.
15. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A et al. (2005). Cancer statistics, 2005. CA Cancer J Clin 55: 10-30. (Pubitemid 40310185)
16. Johnson SK, Kerr KM, Chapman AD, Kennedy MM, King G, Cockburn JS et al. (2000). Immune cell infiltrates and prognosis in primary carcinoma of the lung. Lung Cancer 27: 27-35.
17. Kim WS, Park C, Jung YS, Kim HS, Han J, Park CH et al. (1999). Reduced transforming growth factor-beta type II receptor (TGF-beta RII) expression in adenocarcinoma of the lung. Anticancer Res 19: 301-306. (Pubitemid 29168253)
18. Kobayashi K, Hernandez LD, Galan JE, Janeway Jr CA, Medzhitov R, Flavell RA. (2002). IRAK-M is a negative regulator of Toll-like receptor signaling. Cell 110: 191-202. (Pubitemid 34876547)
19. Kong F, Jirtle RL, Huang DH, Clough RW, Anscher MS. (1999). Plasma transforming growth factor-beta1 level before radiotherapy correlates with long term outcome of patients with lung carcinoma. Cancer 86: 1712-1719. (Pubitemid 29513039)
20. Letterio JJ, Roberts AB. (1998). Regulation of immune responses by TGF-beta. Annu Rev Immunol 16: 137-161.
21. Lewis CE, Pollard JW. (2006). Distinct role of macrophages in different tumor microenvironments. Cancer Res 66: 605-612. (Pubitemid 43165918)
22. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. (2006). Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24: 99-146.
23. Mantovani A, Bottazzi B, Colotta F, Sozzani S, Ruco L. (1992). The origin and function of tumor-associated macrophages. Immunol Today 13: 265-270.
24. Mantovani A, Sozzani S, Locati M, Allavena P, Sica A. (2002). Macrophage polarization: tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. Trends Immunol 23: 549-555. (Pubitemid 35223554)
25. McCartney-Francis N, Jin W, Wahl SM. (2004). Aberrant Toll receptor expression and endotoxin hypersensitivity in mice lacking a functional TGF-beta 1 signaling pathway. J Immunol 172: 3814-3821. (Pubitemid 38337967)
26. Moustakas A, Heldin CH. (2003). Ecsit-ement on the crossroads of Toll and BMP signal transduction. Genes Dev 17: 2855-2859. (Pubitemid 37523149)
27. Mytar B, Woloszyn M, Szatanek R, Baj-Krzyworzeka M, Siedlar M, Ruggiero I et al. (2003). Tumor cell-induced deactivation of human monocytes. J Leukoc Biol 74: 1094-1101. (Pubitemid 38040331)
28. Naiki Y, Michelsen KS, Zhang W, Chen S, Doherty TM, Arditi M. (2005). Transforming growth factor-beta differentially inhibits MyD88-dependent, but not TRAM- and TRIF-dependent, lipo-polysaccharide-induced TLR4 signaling. J Biol Chem 280: 5491-5495. (Pubitemid 40280025)
29. Pan H, Ding E, Hu M, Lagoo AS, Datto MB, Lagoo-Deenadayalan SA. (2010). SMAD4 is required for development of maximal endotoxin tolerance. J Immunol 184: 5502-5509.
30. Pardoll D. (2003). Does the immune system see tumors as foreign or self? Annu Rev Immunol 21: 807-839. (Pubitemid 37174548)
31. Pollard JW. (2004). Tumour-educated macrophages promote tumour progression and metastasis. Nat Rev Cancer 4: 71-78. (Pubitemid 38082155)
32. Reddy RC, Keshamouni VG, Jaigirdar SH, Zeng X, Leff T, Thannickal VJ et al. (2004). Deactivation of murine alveolar macrophages by peroxisome proliferator-activated receptor-gamma ligands. Am J Physiol Lung Cell Mol Physiol 286: L613-L619. (Pubitemid 38233634)
33. Rosati O, Martin MU. (2002). Identification and characterization of murine IRAK-M. Biochem Biophys Res Commun 293: 1472-1477. (Pubitemid 34681043)
34. Scagliotti G, Novello S. (2003). Adjuvant chemotherapy after complete resection for early stage NSCLC. Lung Cancer 42(Suppl 1): S47-S51. (Pubitemid 37378186)
35. Schnare M, Barton GM, Holt AC, Takeda K, Akira S, Medzhitov R. (2001). Toll-like receptors control activation of adaptive immune responses. Nat Immunol 2: 947-950. (Pubitemid 32976167)
36. Seya T, Akazawa T, Uehori J, Matsumoto M, Azuma I, Toyoshima K. (2003). Role of toll-like receptors and their adaptors in adjuvant immunotherapy for cancer. Anticancer Res 23: 4369-4376. (Pubitemid 37474889)
37. Shedden K, Taylor JM, Enkemann SA, Tsao MS, Yeatman TJ, Gerald WL et al. (2008). Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 14: 822-827.
38. Souquet PJ, Geriniere L. (2001). The role of chemotherapy in early stage of non-small cell lung cancer. Lung Cancer 34(Suppl 2): S155-S158. (Pubitemid 33101860)
39. Toonkel RL, Borczuk AC, Powell CA. (2010). TGF-beta signaling pathway in lung adenocarcinoma invasion. J Thorac Oncol 5: 153-157.
40. Van 't Veer C, van den Pangaart PS, van Zoelen MA, de Kruif M, Birjmohun RS, Stroes ES et al. (2007). Induction of IRAK-M is associated with lipopolysaccharide tolerance in a human endo-toxemia model. J Immunol 179: 7110-7120.
41. Wesche H, Gao X, Li X, Kirschning CJ, Stark GR, Cao Z. (1999). IRAK-M is a novel member of the Pelle/interleukin-1 receptor-associated kinase (IRAK) family. J Biol Chem 274: 19403-19410.
42. Xiao C, Shim JH, Kluppel M, Zhang SS, Dong C, Flavell RA et al. (2003). Ecsit is required for Bmp signaling and mesoderm formation during mouse embryogenesis. Genes Dev 17: 2933-2949. (Pubitemid 37523157)
43. Xie Q, Gan L, Wang J, Wilson I, Li L. (2007). Loss of the innate immunity negative regulator IRAK-M leads to enhanced host immune defense against tumor growth. Mol Immunol 44: 3453-3461. (Pubitemid 46754450)
44. Yamaguchi H, Pixley F, Condeelis J. (2006). Invadopodia and podosomes in tumor invasion. Eur J Cell Biol 85: 213-218.